Effects of lipid lowering therapy on progression of coronary and carotid artery disease

被引：35

作者：

Ballantyne, CM ^{[1
]}

Herd, JA ^{[1
]}

Dunn, JK ^{[1
]}

Jones, PH ^{[1
]}

Farmer, JA ^{[1
]}

Gotto, AM ^{[1
]}

机构：

[1] Baylor Coll Med, Houston, TX 77030 USA

来源：

CURRENT OPINION IN LIPIDOLOGY | 1997年 / 8卷 / 06期

关键词：

D O I：

10.1097/00041433-199712000-00006

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Recent data have extended the benefit of lipid lowering therapy to patients with only mildly to moderately elevated LDL-cholesterol, which is typical of patients with coronary artery disease. Meta-analysis of clinical trials of statin therapy with similar sample sizes indicated that the LDL-cholesterol level on treatment was as good a predictor of angiographic benefit as was the percentage reduction in LDL-cholesterol. We review evidence that management of triglyceride-rich lipoproteins, HDL, fibrinogen, lipoprotein particle size, LDL-oxidation, and lipoprotein (a) may also favorably influence atherosclerotic progression. Angiographic and arterial ultrasound trials of lipid lowering therapy have demonstrated benefits on disease progression that are consistent with benefits on myocardial infarction, stroke, and death reported in larger, lengthier trials. (C) Rapid Science Publishers.

引用

页码：354 / 361

页数：8

共 45 条

[1] Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease - The LDL-apheresis atherosclerosis regression study (LAARS) [J].

Aengevaeren, WRM ;

Kroon, AA ;

Stalenhoef, AFH ;

Uijen, GJH ;

vanderWerf, T .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 28 (07) :1696-1704

[2]

Andrews TC, 1997, CIRCULATION, V95, P324

[3]

[Anonymous], 1994, CIRCULATION

[4] Progression of coronary artery disease predicts clinical coronary events - Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study [J].

Azen, SP ;

Mack, WJ ;

CashinHemphill, L ;

LaBree, L ;

Shircore, AM ;

Selzer, RH ;

Blankenhorn, DH ;

Hodis, HN .

CIRCULATION, 1996, 93 (01) :34-41

[5] CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY - THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS) [J].

BLANKENHORN, DH ;

AZEN, SP ;

KRAMSCH, DM ;

MACK, WJ ;

CASHINHEMPHILL, L ;

HODIS, HN ;

DEBOER, LWV ;

MAHRER, PR ;

MASTELLER, MJ ;

VAILAS, LI ;

ALAUPOVIC, P ;

HIRSCH, LJ .

ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) :969-976

[6] CHANGES IN SEQUENTIAL CORONARY ARTERIOGRAMS AND SUBSEQUENT CORONARY EVENTS [J].

BUCHWALD, H ;

MATTS, JP ;

FITCH, LL ;

CAMPOS, CT ;

SANMARCO, ME ;

AMPLATZ, K ;

CASTANEDAZUNIGA, WR ;

HUNTER, DW ;

PEARCE, MB ;

BISSETT, JK ;

EDMISTON, WA ;

SAWIN, HS ;

WEBER, FJ ;

VARCO, RL ;

CAMPBELL, GS ;

YELLIN, AE ;

SMINK, RD ;

LONG, JM ;

HANSEN, BJ ;

CHALMERS, TC ;

MEIER, P ;

STAMLER, J .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (11) :1429-1433

[7]

Campeau L, 1997, NEW ENGL J MED, V336, P153

[8] PRAVASTATIN, LIPIDS, AND ATHEROSCLEROSIS IN THE CAROTID ARTERIES (PLAC-II) [J].

CROUSE, JR ;

BYINGTON, RP ;

BOND, MG ;

ESPELAND, MA ;

CRAVEN, TE ;

SPRINKLE, JW ;

MCGOVERN, ME ;

FURBERG, CD .

AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (07) :455-459

[9] Reductase inhibitor monotherapy and stroke prevention [J].

Crouse, JR ;

Byington, RP ;

Hoen, HM ;

Furberg, CD .

ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (12) :1305-1310

[10] Secondary preventive potential of lipid-lowering drugs - The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) [J].

deFaire, U ;

Ericsson, CG ;

Grip, L ;

Nilsson, J ;

Svane, B ;

Hamsten, A .

EUROPEAN HEART JOURNAL, 1996, 17 :37-42

← 1 2 3 4 5 →